A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders — iNCGS

Growth Hormone Disorders Clinical Trial

Official title:
International Cooperative Growth Study (iNCGS) Post Marketing Surveillance Program for NutropinAq® [Somatropin (rDNA Origin) Injection]

Status Completed

Clinical Trial Summary

This study is a multicenter, open label, observational, post marketing surveillance study of NutropinAq® in Austria, France, Germany, Italy, Spain, Romania and United Kingdom to collect long-term safety and effectiveness information on NutropinAq® during treatment of paediatric growth disorders.

Clinical Trial Description

The objective of this study is to collect long term safety and effectiveness information on Ipsen's growth hormone (GH) NutropinAq® regarding treatment of paediatric growth disorders for which GH is indicated. ;

Study Design

Related Conditions & MeSH terms

Growth Hormone Disorders

Clinical Trial Details

NCT number	NCT00455728
Study type	Observational
Source	Ipsen
Contact
Status	Completed
Phase
Start date	June 2006
Completion date	December 2016

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00455884` - A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency